Related Experiment Video
Updated: Feb 5, 2026
A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis
Published on: October 24, 2015
Immunotherapy of hepatocellular carcinoma
Bruno Sangro1,1, Daniel Palmer2,2, Ignacio Melero3,3
1Liver Unit, Clínica Universidad de Navarra, and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD); Avda. Pio XII 36. 31008-Pamplona, Spain.
Abstract:
Newer immunotherapy agents may break the barrier that tumors create to evade the attack from the immune system. Dendritic cell vaccination has shown encouraging clinical activity and a favorable safety profile in advanced tumor stages. However, optimal cell maturation status, choice of tumor antigens and route of administration have not been established. Single or multiple peptides derived from tumor-associated antigens may also be used for cancer vaccination. Intratumoral delivery of oncolytic viruses expressing immunostimulating cytokines like GM-CSF have produced stimulating clinical results that need further verification. But it is probably T-cell checkpoint modulation with monoclonal antibodies that has attracted the highest expectations. Promising activity has been reported for tremelimumab, a CTLA-4 inhibitor, and a clinical trial testing the PD-1 antibody nivolumab is underway. Future progress will probably come from a better understanding of the mechanisms of cancer-related immunosuppression, improvement in agents and strategies and combination of the available therapeutic tools.
Insights
New immunotherapies, including dendritic cell vaccines and T-cell checkpoint inhibitors, show promise in overcoming tumor immune evasion. Further research is needed to optimize strategies and combine therapeutic tools for enhanced cancer treatment.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Tumors create barriers to evade immune system attacks.
- Immunotherapy agents aim to overcome these barriers.
- Dendritic cell vaccination shows clinical activity but requires optimization.
Purpose of the Study:
- To review newer immunotherapy agents for cancer treatment.
- To discuss challenges and future directions in cancer immunotherapy.
- To highlight the potential of T-cell checkpoint modulation.
Main Methods:
- Review of current immunotherapy strategies including dendritic cell vaccination, peptide vaccines, oncolytic viruses, and T-cell checkpoint inhibitors.
- Discussion of clinical activity and safety profiles of various agents.
- Exploration of ongoing clinical trials and future research needs.
Main Results:
- Dendritic cell vaccination demonstrates encouraging clinical activity and safety.
- Intratumoral delivery of oncolytic viruses shows promising results.
- CTLA-4 inhibitor (tremelimumab) and PD-1 antibody (nivolumab) exhibit promising activity.
Conclusions:
- Optimizing dendritic cell vaccination requires further study on maturation, antigens, and administration.
- T-cell checkpoint modulation with monoclonal antibodies holds significant promise.
- Future progress depends on understanding immunosuppression, improving agents, and combining therapies.
Related Concept Videos
01:27Tumor Immunotherapy
02:35Chromatin Position Affects Gene Expression
Topologically Associated Domains (TADs)
The 3-dimensional positioning of chromatin in the nucleus influences the...